150 related articles for article (PubMed ID: 16136199)
1. The clinical use of tumor makers in select cancers: are you confident enough to discuss them with your patients?
Sanchez Yamamoto D; Hallquist Viale P; Roesser K; Lin A
Oncol Nurs Forum; 2005 Sep; 32(5):1013-22; quiz 1023-4. PubMed ID: 16136199
[TBL] [Abstract][Full Text] [Related]
2. The cancer cell secretome: a good source for discovering biomarkers?
Pavlou MP; Diamandis EP
J Proteomics; 2010 Sep; 73(10):1896-906. PubMed ID: 20394844
[TBL] [Abstract][Full Text] [Related]
3. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract][Full Text] [Related]
4. Use of multiple markers to enhance clinical utility.
Mercer DW
Immunol Ser; 1990; 53():39-54. PubMed ID: 2100569
[No Abstract] [Full Text] [Related]
5. Reaching agreement on tumor markers.
Check W
CAP Today; 1998 Jul; 12(7):1, 34, 38 passim. PubMed ID: 10181878
[No Abstract] [Full Text] [Related]
6. A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential.
Kumar S; Nag A; Mandal CC
Curr Drug Targets; 2015; 16(12):1381-403. PubMed ID: 25808651
[TBL] [Abstract][Full Text] [Related]
7. Practice guidelines for tumor marker use in the clinic.
Sturgeon C
Clin Chem; 2002 Aug; 48(8):1151-9. PubMed ID: 12142367
[TBL] [Abstract][Full Text] [Related]
8. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening.
Smith RA; Andrews K; Brooks D; DeSantis CE; Fedewa SA; Lortet-Tieulent J; Manassaram-Baptiste D; Brawley OW; Wender RC
CA Cancer J Clin; 2016; 66(2):96-114. PubMed ID: 26797525
[TBL] [Abstract][Full Text] [Related]
9. [Surface enhanced laser desorption/ionization (SELDI): proteomics technology and its application in oncology].
Espejel F; Roa JC
Med Clin (Barc); 2008 Sep; 131(8):312-7. PubMed ID: 18803927
[TBL] [Abstract][Full Text] [Related]
10. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
[TBL] [Abstract][Full Text] [Related]
11. Molecular diagnostic testing in breast cancer.
Berse B; Lynch JA
Semin Oncol Nurs; 2015 May; 31(2):108-21. PubMed ID: 25951740
[TBL] [Abstract][Full Text] [Related]
12. [9th European Cancer Conference: EECO 9 Hamburg (Germany), 14-18 September, 1997].
Baumann P
Cancer Radiother; 1998; 2(1):72-5. PubMed ID: 9749099
[No Abstract] [Full Text] [Related]
13. ACS releases updated guidelines on cancer screening.
Lambert M
Am Fam Physician; 2012 Sep; 86(6):571, 576-7. PubMed ID: 23062051
[No Abstract] [Full Text] [Related]
14. Cancer screening in the primary care setting: the role of the primary care physician in screening for breast, cervical, colorectal, lung, ovarian, and prostate cancers.
Miser WF
Prim Care; 2007 Mar; 34(1):137-67. PubMed ID: 17481991
[No Abstract] [Full Text] [Related]
15. Evaluation of TATI and other markers in solid tumors.
Taccone W; Mazzon W; Belli M
Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
[TBL] [Abstract][Full Text] [Related]
16. Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer.
Luo L; Dong LY; Yan QG; Cao SJ; Wen XT; Huang Y; Huang XB; Wu R; Ma XP
Asian Pac J Cancer Prev; 2014; 15(20):8529-38. PubMed ID: 25374164
[TBL] [Abstract][Full Text] [Related]
17. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1998 Feb; 16(2):793-5. PubMed ID: 9469371
[TBL] [Abstract][Full Text] [Related]
18. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
Wright GL
Expert Rev Mol Diagn; 2002 Nov; 2(6):549-63. PubMed ID: 12465452
[TBL] [Abstract][Full Text] [Related]
19. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
Kramer BS; Gohagan J; Prorok PC; Smart C
Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
